JP2021503960A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503960A5
JP2021503960A5 JP2020546302A JP2020546302A JP2021503960A5 JP 2021503960 A5 JP2021503960 A5 JP 2021503960A5 JP 2020546302 A JP2020546302 A JP 2020546302A JP 2020546302 A JP2020546302 A JP 2020546302A JP 2021503960 A5 JP2021503960 A5 JP 2021503960A5
Authority
JP
Japan
Prior art keywords
receptor
pharmaceutical composition
vector
engineered
engineered receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503960A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/062575 external-priority patent/WO2019104307A1/en
Publication of JP2021503960A publication Critical patent/JP2021503960A/ja
Publication of JP2021503960A5 publication Critical patent/JP2021503960A5/ja
Priority to JP2024105712A priority Critical patent/JP2024160218A/ja
Pending legal-status Critical Current

Links

JP2020546302A 2017-11-27 2018-11-27 神経疾患のための組成物および方法 Pending JP2021503960A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024105712A JP2024160218A (ja) 2017-11-27 2024-06-28 神経疾患のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762590911P 2017-11-27 2017-11-27
US62/590,911 2017-11-27
US201862659911P 2018-04-19 2018-04-19
US62/659,911 2018-04-19
PCT/US2018/062575 WO2019104307A1 (en) 2017-11-27 2018-11-27 Compositions and methods for neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024105712A Division JP2024160218A (ja) 2017-11-27 2024-06-28 神経疾患のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021503960A JP2021503960A (ja) 2021-02-15
JP2021503960A5 true JP2021503960A5 (cg-RX-API-DMAC7.html) 2022-01-04

Family

ID=66632192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546302A Pending JP2021503960A (ja) 2017-11-27 2018-11-27 神経疾患のための組成物および方法
JP2024105712A Pending JP2024160218A (ja) 2017-11-27 2024-06-28 神経疾患のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024105712A Pending JP2024160218A (ja) 2017-11-27 2024-06-28 神経疾患のための組成物および方法

Country Status (12)

Country Link
US (2) US10538571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3716990A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021503960A (cg-RX-API-DMAC7.html)
KR (2) KR20200112811A (cg-RX-API-DMAC7.html)
CN (1) CN111741760A (cg-RX-API-DMAC7.html)
AU (2) AU2018373279B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082907A1 (cg-RX-API-DMAC7.html)
IL (2) IL274702B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020005470A (cg-RX-API-DMAC7.html)
SG (1) SG11202004488TA (cg-RX-API-DMAC7.html)
WO (1) WO2019104307A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408862B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法
US20230102192A1 (en) * 2020-02-20 2023-03-30 The Regents Of The University Of California Therapies for the treatment of diseases and disorders associated with abnormal expression of a neural-associated gene
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2022067044A1 (en) * 2020-09-25 2022-03-31 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
JP2024505197A (ja) * 2021-01-25 2024-02-05 トレイムス バイオ, インコーポレイテッド 焦点てんかんおよび神経因性疼痛を処置するためのアデノ随伴ウイルスカプシドおよび操作されたリガンド依存性イオンチャネル
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN113730809B (zh) * 2021-10-09 2024-08-16 科悦医疗(苏州)有限公司 一种非侵入式迷走神经联合骶神经刺激装置
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
CN119343455A (zh) * 2022-01-31 2025-01-21 特拉梅斯生物股份有限公司 用于治疗癫痫和神经性疼痛的表达盒
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
AU2023222147A1 (en) * 2022-02-18 2024-09-12 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2025015092A1 (en) * 2023-07-10 2025-01-16 Kriya Therapeutics, Inc. Novel cam-kinase promoter and uses thereof for treating nervous system disorders
CN121866054A (zh) * 2023-08-16 2026-04-14 拜尔吉生物股份有限公司 用于治疗癫痫发作的方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3628691B2 (ja) * 1993-03-08 2005-03-16 メルク エンド カンパニー インコーポレーテッド ヒト神経細胞性ニコチン性アセチルコリン受容体組成物およびそれらの使用方法
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
WO1997035478A1 (en) 1996-03-26 1997-10-02 The Regents Of The University Of California Selective target cell activation by expression of a g protein-coupled receptor activated superiorly by synthetic ligand
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2001257378A1 (en) 2000-04-29 2001-11-12 Millennium Pharmaceuticals, Inc. 23949 and 32391, human ion channels and uses thereof
US7883846B2 (en) 2002-05-31 2011-02-08 Sloan-Kettering Institute For Cancer Research Heterologous stimulus-gated ion channels and methods of using same
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US9624288B2 (en) * 2012-12-10 2017-04-18 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered receptors and their use
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
US10682424B2 (en) 2015-03-31 2020-06-16 New York University Compositions and method for reducing seizures
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders

Similar Documents

Publication Publication Date Title
JP2022545226A5 (cg-RX-API-DMAC7.html)
JP2019141076A5 (cg-RX-API-DMAC7.html)
JP2022068181A5 (cg-RX-API-DMAC7.html)
JP2020528734A5 (cg-RX-API-DMAC7.html)
JP2019089787A5 (cg-RX-API-DMAC7.html)
JP2018508519A5 (cg-RX-API-DMAC7.html)
JP2021505133A5 (cg-RX-API-DMAC7.html)
JP2025120285A5 (cg-RX-API-DMAC7.html)
JP2023527354A5 (cg-RX-API-DMAC7.html)
JP2020534788A5 (cg-RX-API-DMAC7.html)
JP2022502056A5 (cg-RX-API-DMAC7.html)
JP2020513811A5 (cg-RX-API-DMAC7.html)
JP2020522259A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
JP2003519481A5 (cg-RX-API-DMAC7.html)
JP2009513162A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2022529782A5 (cg-RX-API-DMAC7.html)
JP2021500922A5 (cg-RX-API-DMAC7.html)
JP2014510519A5 (cg-RX-API-DMAC7.html)
JP2023537625A5 (cg-RX-API-DMAC7.html)
RU2019126509A (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
JP2023514446A5 (cg-RX-API-DMAC7.html)
JP2023535956A5 (cg-RX-API-DMAC7.html)
JP2010519931A5 (cg-RX-API-DMAC7.html)